Liquid pharmaceutical composition for the treatment of a posterior eye disease

Patent metadata

Field	Value
Publication number	US-10064944-B2
Application number	US-201514973461-A
Country	US
Kind code	B2
Filing date	Dec 17, 2015
Priority date	Nov 11, 2010
Publication date	Sep 4, 2018
Grant date	Sep 4, 2018

Abstract

The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

First claim

The invention claimed is:

1. A method for the stabilization, management or cure, or improvement of the symptoms, of a disease or condition affecting a tissue of the posterior segment of an eye of a patient, comprising topical administration to the surface of the eye of a pharmaceutical composition comprising an active ingredient dissolved in a non-aqueous, physiologically tolerable, liquid vehicle having a density of at least 1.2 g/ml wherein the liquid vehicle comprises a semifluorinated alkane, wherein the semifluorinated alkane has a refractive index in the range from 1.3204 to 1.3494.

2. The method of claim 1 , wherein the method further includes a time period subsequent to the administration of the composition during said period the patient is in a supine position facing upwards, said period being from about 15minutes to about 6 hours to allow the composition to migrate from the site of administration to a site in the posterior segment of the eye.

3. The method of claim 1 , wherein the patient is affected by a disease or condition selected from the group consisting of age-related macular degeneration, diabetic retinopathy, glaucoma, retinitis pigmentosa, and cytomegalovirus retinitis.

4. The method of claim 1 , wherein the liquid vehicle further comprises one or more compounds selected from the group consisting of perfluorocarbons, polysiloxanes, and mixtures thereof.

5. The method of claim 1 , wherein the semifluorinated alkane is a compound of the formula
RFRH
or of formula
RFRHRF

wherein RF is a perfluorinated hydrocarbon segment with 20 or less carbon atoms, and
wherein RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms.

6. The method of claim 5 , wherein the semifluorinated alkane is a compound of formula
RFRH
wherein RF is a linear perfluorinated hydrocarbon segment with 3 to 10 carbon atoms, and
wherein RH is a linear alkyl group with 3 to 10 carbon atoms.

7. The method of claim 6 , wherein the semifluorinated alkane is selected from the group consisting of F4H5, F6H6 and F6H8.

8. The method of claim 1 , wherein the liquid vehicle has a density of at least about 1.35 g/ml.

9. The method of claim 1 , wherein the liquid vehicle has a boiling point of at least about 120° C.

10. The method of claim 1 , wherein the pharmaceutical composition has a dynamic viscosity of not more than about 5 mPas.

11. The method of claim 1 , wherein the semifluorinated alkane has a refractive index of 1.3432 at 20° C.

12. The method of claim 1 , wherein the pharmaceutical composition consists of the active ingredient dissolved in the semifluorinated alkane.

13. The method of claim 1 , wherein the pharmaceutical composition further comprises one or more excipients selected from the group consisting of co-solvents, surfactants, stabilisers, antioxidants, preservatives, and colouring agents.

14. The method of claim 1 , wherein the pharmaceutical composition is formulated so as to provide for the sustained release of the active ingredient over a period of at least about 24 hours.

15. The method of claim 1 , wherein the pharmaceutical composition comprises the active ingredient in dissolved form, wherein the active ingredient is a cholinergic agent selected from the group consisting of brimonidine, clonidine, dipivefrine, apraclonidine, carbachol, and pilocarpine, and salts or solvates thereof.

16. The method of claim 15 , wherein the active ingredient is brimonidine or a salt or solvate thereof.

17. The method of claim 12 , wherein the active ingredient is selected from the group consisting of latanoprost, bimatoprost, tafluprost, travoprost, unoprostone, triamcinolone, dexamethasone, fluorometholone, hydrocortisone, prednisolone, rimexolone, aureomycin, azithromycin, gentamycin, ciprofloxacin, ofloxacin, fusidic acid, kanamycin, levofloxacin, lomefloxacin, oxytetracyclin, tobramycin, natamycin, moxifloxacin, carteolol, timolol, metipranolol, betaxolol, pindolol, levobunolol, brimonidine, clonidine, dipivefrine, apraclonidine, carbachol, pilocarpine, brinzolamide, dorzolamide, aciclovir, trifluridine, ganciclovir, diclofenac, bromfenac, ketorolac, flurbiprofen, indomethacin, and salts and solvates thereof.

Assignees

• Wilson Clive G
• Novaliq Gmbh

Inventors

• Wilson Clive G

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title